KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Retained Earnings: 2009-2025

Historic Retained Earnings for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to -$1.3 billion.

  • Rigel Pharmaceuticals' Retained Earnings rose 8.07% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 8.07%. This contributed to the annual value of -$1.4 billion for FY2024, which is 1.24% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Retained Earnings stood at -$1.3 billion for Q3 2025, which was up 2.12% from -$1.3 billion recorded in Q2 2025.
  • Rigel Pharmaceuticals' Retained Earnings' 5-year high stood at -$1.3 billion during Q1 2021, with a 5-year trough of -$1.4 billion in Q2 2024.
  • Its 3-year average for Retained Earnings is -$1.4 billion, with a median of -$1.4 billion in 2023.
  • In the last 5 years, Rigel Pharmaceuticals' Retained Earnings fell by 6.70% in 2022 and then increased by 8.07% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Retained Earnings (Quarterly) stood at -$1.3 billion in 2021, then dropped by 4.42% to -$1.4 billion in 2022, then dropped by 1.81% to -$1.4 billion in 2023, then increased by 1.24% to -$1.4 billion in 2024, then rose by 8.07% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.3 billion for Q2 2025, and -$1.4 billion during Q1 2025.